GlassScriptPhysician profile
Abiodun P Badewa
NPI 1558562603
$1,026.25
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $256 · 2021: $75.45 · 2022: $213 · 2023: $253 · 2024: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $644.11 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $169.97 | 2020-2024 | Airsupra, Farxiga, Fasenra |
| Shield Therapeutics INC | $34.19 | 2023-2024 | Accrufer |
| Dexcom, INC. | $31.07 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $30.07 | 2019 | |
| Galt Pharmaceuticals, LLC | $19.69 | 2023 | Orphengesic Forte |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.38 | 2020 | |
| Genentech USA, INC. | $18.66 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.43 | 2019 | |
| Scynexis, INC. | $16.46 | 2022 | |
| Zyla Life Sciences, INC. | $12.68 | 2020 | |
| Biogen, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abiodun Badewa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.